Press Room

Latest

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001


News - 2014

Uscom – Distribution and Sales Manager Appointment

December 17th, 2014

Uscom announced to the market it had appointed Ms Denise Pater to the position of Distribution and Sales Manager.

Ms Pater has nearly 20 years experience in medical device distribution, sales, marketing, business development and management, having previously been employed by GE Healthcare, Datex-Omeda, Medtel and Ramsay Healthcare. Ms Pater came to medical device management with a critical care clinical nursing background.

Ms Pater’s role will be to co-ordinate and target current resources within the company to support and motivate the growing worldwide Uscom distribution network, and to develop specific new business initiatives. Denise will be responsible for management of the distribution and sales efforts for both the USCOM 1A and the Uscom BP+ technologies globally.

Ms Pater said “Uscom has a growing global reputation as an outstanding and innovative medical technology company with great cardiovascular products, and joining the Company now, as it enters a rapid growth phase, is very exciting. I intend to improve the effectiveness of our growing distribution channels so we can optimise the sales opportunities and enlist new and larger distributors. I’m anticipating healthy revenue growth off the back of improved current distribution, and new appointments and marketing activities. I’m particularly optimistic about the potential for the newly developed Uscom BP+ central blood pressure monitor in hypertension trials with global pharmaceutical companies. Uscom BP+ is a real solution for them as they seek to improve their research methods and reduce the cost of their trials.”

Executive Chairman of Uscom, Dr Rob Phillips said “Denise is an experienced and respected member in the medical technology world and her contribution to Uscom management will be vital as we accelerate into our growth phase. Denise is an important next step in our expansion, and her skills in distributor management, marketing and sales compliment our already strong team. Her objective is to focus and co-ordinate Uscom resources to drive our global distribution partners and achieve significant sales and revenue growth.”

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the way cardiovascular diseases are diagnosed and treated. The devices have specific application in hypertension, heart failure and sepsis, and improve the use of fluid, inotropes and vasoactive therapies.

Uscom - Johnson & Johnson Innovation Company of the Year

October 30th, 2014

Uscom, a revenue stage, cardiovascular medical devices company, today announced to the market it had been awarded the Johnson & Johnson Innovation Industry Excellence Company of the Year Award for 2014 at the Annual AusBiotech Life Sciences Conference.

The Award recognises established biotechnology companies that have demonstrated significant achievements and covers companies working in the fields of biotechnology or life sciences, including but not limited to the medical diagnostics or devices, pharmaceutical and agricultural sectors. Criteria for the award includes transactions, product pipeline, IP, Company strategy and /or revenue.

The award was presented to Dr Rob Phillips, CEO and founder of Uscom Limited, by Dr Dong Wu, Head of the Johnson & Johnson, Asia Pacific Innovation Centre, and Kathy Connell, the Director of New Ventures, ANZ, Johnson & Johnson, Asia Pacific Innovation Centre.

Executive Chairman of Uscom, Dr Rob Phillips said “It is a great privilege to be recognised with this Johnson & Johnson Innovation Industry Excellence Company of the Year award. This award acknowledges the many individual efforts, over time, that have contributed to the growth of our Australian Biotechnology Company. While our mission is to save lives through commercialisation of cost effective medical devices, the corporate model for Uscom is excellence in business, built on excellence in science for the benefit of global health, and we are delighted to have these goals endorsed by receiving this award.”

About Johnson & Johnson Innovation

The Asia Pacific Innovation Center is part of Johnson & Johnson Innovation, a division of Johnson & Johnson (China) Investment Ltd. Johnson & Johnson Innovation focuses on accelerating early-stage innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and diagnostics and consumer companies of Johnson & Johnson. Johnson & Johnson Innovation includes local deal-making capabilities with the flexibility to adapt deal structures to match early-stage opportunities and establish novel collaborations that speed development of innovations to solve unmet needs in patients. For more information please visit: www.jnjinnovation.com.

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the way cardiovascular diseases are diagnosed and treated. The devices have specific application in hypertension, heart failure and sepsis, and improve the use of fluid, inotropes and vasoactive therapies.

Links:
Johnson & Johnson Innovation
Johnson & Johnson Press Release

USCOM Sale into Space Program

October 27th, 2014

Uscom Limited has announced the sale of an USCOM unit to the Russian Federal Space Agency.

The USCOM 1A has been commissioned for high level research of cardiovascular physiology in astronauts before, during and after space travel. The influence of weightlessness on the circulation is not well understood in part because there has previously not been available an accurate, non-invasive method to monitor the circulation. It is anticipated that the use of the USCOM device will provide an improved understanding of the circulation of astronauts in space.

Executive Chairman of Uscom, Dr Rob Phillips said “This is another area of circulatory research which can be advanced by the USCOM technology. The high accuracy and sensitivity of the USCOM device results in many unique applications in which USCOM can improve our understanding of physiology and contribute to the global body of cardiovascular knowledge. The results of the USCOM in space physiology research may be translated into improved clinical care in heart failure, hypertension, sepsis and the guidance of fluid therapy.”

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the way cardiovascular diseases, including hypertension, heart failure and sepsis are diagnosed and treated, and improving guidance of fluid, inotropes and vasoactive therapies.

Uscom Finalist in NSW Premier’s Export Awards

September 17th, 2014

Uscom is pleased to announce it has been selected as a finalist in the NSW Premier’s Export Awards.

These annual Awards recognise excellence in the export of goods and services by NSW businesses and honours the state’s top exporters, raising their profile and bringing valuable business opportunities. The Awards recognise outstanding international success in the export of products, technology, equipment or services from NSW. NSW Trade & Investment is the principal sponsor of the 2014 Premier’s NSW Export Awards in conjunction with the Export Council of Australia.

Lisa McAuley, COO of the Export Council of Australia said “The Export Council of Australia congratulates Uscom Limited on being named a finalist in the 2014 Premier of NSW Export Awards and wishes them well at the awards ceremony on the 23rd October in Sydney.”

Executive Chairman of Uscom, Dr Rob Phillips said, “We are delighted to receive this recognition from the NSW Premier and The Export Council of Australia. Uscom is very focused on international markets and sells more than 95% of its products overseas. In the last year we have doubled our international distribution and written nearly $20m in distribution contracts. USCOM devices are being used in markets as diverse as Eastern Europe, South Africa, Russia, China, United Kingdom, the Middle East, USA and Mexico. We recently sold an Uscom 1A unit to a charity for use in the Paediatric ICU Department of the Timisoara Hospital in Romania. The commercialization of Australian technology and sales into global markets is vital for the health of the Australian economy, and we are proud to be a leader in that process.”

About the NSW Premier’s Export Awards

USCOM Part of World Sepsis Day in London

September 12th, 2014

The BUSH protocol and other applications of the USCOM device in sepsis and septic shock are being presented at the World Sepsis Day symposium at the King’s College, London on World Sepsis Day.

World Sepsis Day is on the 13th September 2014 and is an initiative of the Global Sepsis Alliance, an organisation committed to the support of caregivers around the world as they seek to better understand and combat sepsis. As part of the World Sepsis Day Professor Brendan Smith from Australia has been invited to join with Professor Joe Carcillo from Children’s Hospital Pittsburgh, USA and Dr Akash Deep from King’s College in London to present at the King’s College symposium in London on sepsis in children. Each of these presenters uses USCOM to manage sepsis in children.

Professor Brendan Smith from Australia will summarise results from his 6 year study of management outcomes of sepsis patients using USCOM in his BUSH protocol which has resulted in a reduction of mortality from the global average of 30-35% to 7%. Professor Smith’s pioneering research in regional NSW to improve management of sepsis and septic shock, using the Australian invented USCOM, is creating waves worldwide. Professor Smith and his team are at the forefront of the medical defense against this global epidemic. Professor Smith said, “there are no two ways about it, the USCOM device is helping us save lives daily.

Dr Deep, Director of the Paediatric ICU at Kings College London said “USCOM has changed the way I look at the cardiovascular system of my patients, and has now been established as the standard of care.

Executive Chairman of Uscom, Dr Rob Phillips said, “Sepsis is a global medical emergency which may kill one third of our friends and family, from newborns, children, in pregnancy, adults and the elderly. We developed USCOM to make a difference and it is changing the way we approach this dangerous disease, and it is saving lives. Professor Smith’s research demonstrated that if the BUSH protocol using USCOM was introduced in Australia there was a predicted saving of 8,237 Australian lives and more than $1billion over the last 6 years. USCOM is an important medical innovation in the fight against sepsis making a significant health economic contribution to health care.”

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices which are changing the way we diagnose and treat cardiovascular diseases, including hypertension, heart failure and sepsis, and improving guidance of fluid, inotropes and vasoactive therapies.

References:

  1. The Lancet Infectious Diseases. For sepsis, the drugs don’t work. Lancet Infect Dis 2012; 12: 89
  2. Adhikari NK, Fowler RA, Bhagwanjee S, Rubenfeld GD. Critical care and the global burden of critical illness in adults. Lancet 2010; 376: 1339-1346
  3. Smith BE, Phillips RA, Madigan V, West MJ. Decreased Mortality, Morbidity and Emergency Transport in Septic Shock; A New Protocol Based on Advanced Noinvasive Haemodynamics (USCOM) and Early Antibiotics. Crit Care Med 2012; 40(12):1023. doi: 10.1097/01.ccm.0000424114.76434.7a
  4. Yealy DM, Kellum JA, Huang DT, and the ProCESS Investigators. A Randomized Trial of Protocol-Based Care for Early Septic Shock. New Engl J Med 2014; DOI: 10.1056/NEJMoa1401602

New USCOM science in critical applications

September 8th, 2014

Four new positive studies demonstrating the widespread clinical applicability of the USCOM 1A have been published.

The studies were from authors affiliated with the Imperial College, London, The Liverpool Women’s College, Liverpool, The Department of Anesthesiology, Gang Gung Hospital, Taiwan, The Department of Medicine at the University of Queensland, and The Great Ormond Street Hospital for Children and the University College, London. The subject of the studies were:

  1. Accuracy and precision of USCOM in pregnancy using 3D comparisons
  2. USCOM fluid guidance in liver transplantation
  3. USCOM fluid guided management in critically ill children
  4. Review of adult, child and neonatal applications of USCOM for fluid management

These 4 studies are in addition to the 36 published during the 2014 financial year, and brings the total number of publications and presentations supporting the USCOM 1A effectiveness to a total in excess of 350. This proof already includes applications in the billion dollar haemodynamic monitoring and hypertension markets. This growing world leading science provides a platform of credibility from which the newly appointed distribution partners can deliver Uscom technologies to market and generate revenue.

Executive Chairman of Uscom, Dr Rob Phillips said, “Uscom Limited was founded on the integrity of the USCOM science, and these publications further define the improvements that USCOM is now making to clinical practice, and remind us that our technology is changing clinical care and can save real lives, daily. Fluid management is the most common critical care intervention, yet approximately 50% of all such interventions are unnecessary and ineffective, and may cause heart failure and death. USCOM has changed the clinical approach to fluid management with a reported 91% success rate in even the most difficult critical care patients, thereby almost eliminating these life threatening complications. This improved guidance of fluid is being applied to the management of sepsis, hypertension, heart failure and liver transplantation, and USCOM is now being adopted as a standard of care by world leading clinicians at major hospitals through out the world.”

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the way we diagnose and treat cardiovascular diseases, including hypertension, heart failure and sepsis, and improving guidance of fluid, inotropes and vasoactive therapies.

References:

  1. McNamara H, Barclay P, Sharma V. Accuracy and precision of the ultrasound cardiac output monitor (USCOM 1A) in pregnancy: comparison with three-dimensional transthoracic echocardiography. Brit J Anaes 2014, doi:10.1093/bja/aeu162
  2. Su BC, Luo CF, Chnag WY, Lee WC, Lin CC. Corrected Flow Time is a Good Indicator for Preload Responsiveness During Living Donor Liver Donation. Transpl Proceed 2014;46:672-674. doi.org/10.1016/j.transproceed.2013.11.021
  3. McLean JRL, Inwald DP. The utility of stroke volume variability as a predictor of fluid responsiveness in critically ill children: a pilot study. Int Care Med 2014;40:288-289. DOI 10.1007/s00134-013-3171-x
  4. Phillips RA, Brierley J. Fluid responsiveness is about stroke volume, and not pulse pressure Yogi: the power of Doppler fluid management and cardiovascular monitoring. J Clin Monit Comput 2014 doi 10.1007/s10877-014-9598-y

TGA Approval for Uscom BP+ Central Blood Pressure

August 25th, 2014

BP+ device now has FDA, CE Mark and TGA approval.

Uscom is pleased to announce notice of the listing of the Uscom BP+ device on the Australian Register of Therapeutic Goods. The Australian Therapeutic Goods Administration (TGA) lists devices which meet Australian Government standards of quality, safety, efficacy and timely availability on the Australian Register of Therapeutic Goods. Listing on the TGA register is essential prior to sale of a medical device in Australia.

The Uscom BP+ uses patent protected suprasystolic oscillometry to measure the blood pressure at the heart, information previously only provided by cardiac catheterization, and which better predicts cardiovascular risk and provides better treatment guidance. The patent protected Uscom suprasystolic oscillometric central blood pressure technology has advantages over simple sub systolic oscillometry, which only measures the cuff blood pressure in the arm. The TGA listing now means the Uscom BP+ can be sold in Australia by distributors and directly by the Company to Hospitals, clinics, researchers and consumers concerned with improved management of hypertension and other diseases related to blood pressure abnormalities such as heart failure. The current global BP device market is estimated at approximately $2b USD and growing at 11.5% per year.

Executive Chairman of Uscom, Dr Rob Phillips said, “Regulatory approval is becoming a significant hurdle for market entry as the regulatory process becomes increasingly complicated. We are delighted to have FDA, CE and now TGA approval for the Uscom BP+, and are currently preparing for Chinese CFDA submission. Australian Doctors are responsive to new and improved technologies and the Uscom supra systolic oscillometric central blood pressure device, the BP+, represents a breakthrough technology in the field. We are now targeting Hospitals, cardiovascular researchers, clinics and individuals with hypertension or heart failure that require highly accurate clinical blood pressure measurements and improved management.”

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the way we diagnose and treat cardiovascular diseases, including hypertension, heart failure and sepsis, and improving guidance of fluid, inotropes and vasoactive therapies.

Uscom Annual Report 2014

August 18th, 2014

Sales up 67%, cash on hand up 192%, and first Uscom BP+ sales

Uscom Limited, a revenue stage, cardiovascular medical devices company, today released its Appendix 4E – Annual Results for the financial year 2014.

During the year, we note the following:

  1. Operations – Revenues from activities up 67%, and cash on hand up 192%
  2. Outcomes – Shareholder equity up 41%, and Uscom capitalised value up 55%
  3. Growth – Successful integration of Pulsecor IP, systems and assets
  4. Milestones – Manufacture of the first Uscom BP+, new USA BP+ patent, and BP+ CE approval
  5. Distribution – Increased Uscom BP+ and USCOM 1A distributors by 12 to 27
  6. Science – 36 new publications for USCOM 1A and BP+

Annual Review
This year has been a year of consolidation and positioning for Uscom. Revenue for 2014 grew by 67% on 2013 to $1,064,666 as a result of increased demand and increased sales of the USCOM 1A. There was a small increase in cost of operations associated with the costs of integrating BP+ assets including IP transfers, regulatory re-registrations and preparation for BP+ manufacture leading to a 5% increase in loss before income tax. Total assets of the Company increased by 34% to $3.77m at year end, while total shareholder equity increased by 41% in the period. We anticipate a further improvement in revenue as the new distributors increase marketing activity which transitions to sales.

We have also expanded our product range in 2014 with the company successfully completing the acquisition of the BP+ technology. We have now fully integrated the product, the IP and the processes into our operations, and have now manufactured the first BP+ devices for commercial sale. We also received CE Mark for BP+, enabling us to sell into Europe, a major commercial opportunity for Uscom.

A major focus for Uscom in 2014 has been the to build our global distribution platform for both the USCOM 1A and the BP+, to secure greater sales and revenues as we move forward. An additional 12 distributors were appointed during the 2104 year taking the total to 27. A key feature of this expanded distribution was the signing of a number of major cornerstone distributors including:

Uscom also built infrastructure to support our commercial activities appointing a global sales manager in the UK, and are also examining outsourced OEM manufacturing providers to enable increased capacity and potentially further margin improvement as demand increases.

We ended the year with cash on hand of $1.6m, an increase of 192% from 2013, as a result of a capital raising which was supported by new and existing institutions and professional investors.

This cash will be used to fund operations as the sales distribution networks for USCOM 1A and the Uscom BP+ become effective and operations profitable in the next year as we anticipate.

There were 36 new publications supporting the utility of USCOM 1A and the BP+ in 2014, taking the Uscom evidence to more than 450 papers particularly in the fields of hypertension, heart failure and sepsis in adults, children and neonates. The BP+ received CE mark and a new USA patent.

Executive Chairman of Uscom, Dr Rob Phillips said “This is a satisfying result and reflects the effort management have put into integrating the Pulsecor assets acquired at the beginning of the period. The costs associated with the BP+ acquisition are integrated in the current annual accounts, yet the revenues are still to flow. We have significantly increased USCOM and BP+ distributors in anticipation of the demand for BP+ and an increasing demand for the USCOM 1A. This positions us well for the year ahead and our focus is directly on sales, distribution and revenue, and our anticipated shift to profitability.”

View the Annual Report

Quarterly Report - Continuing sales growth, up 148% on corresponding period

August 4th, 2014

Uscom, a revenue stage, cardiovascular medical devices company, has released its Appendix 4C – Quarterly Cashflow report for the quarter ended 30 June 2014.

During the Quarter, the highlights were the following:

Business Review

The Company made considerable progress during the Quarter with commercialisation and scale up activities of its lead products the USCOM 1A, which is FDA, CE Mark and TGA approved, and the newly developed Uscom BP+, with FDA, CE Mark and pending TGA.

In relation to the USCOM 1A cardiac output monitoring product, sales continued to grow through the existing sales channels in the USA, China, and the EU and United Kingdom.

As part of its growth strategy, in recent months, Uscom appointed a number of new, highly qualified USCOM 1A distributors in a number of key markets in Europe.  These include SMT Medical which was appointed for the German market, the largest healthcare market in Europe and the third largest market in the world, servicing some 82 million people.  In Sweden and Norway, a market which services approximately 15million people, the Company has appointed Avalon Medical.

In June 2014, the Company appointed Unetixs Vascular, Inc. as non-exclusive distributors for the USCOM 1A product in the US market.  Unetixs specialises in distribution of cadiovascular assessment devices and is a subsidiary of Opto Circuits of India, a global leader in medical devices for the acute and critical care markets.

The Company has also progressed the commercial launch of the Uscom BP+ device, intended for the third quarter of this year.  In June 2014, the Company announced that the first run of 180 Uscom BP+ devices was being manufactured in Uscom’s Sydney facility.  This also completes the transfer of IP, technology and processes associated with the acquisition of assets from Pulsecor last year.  We are now preparing to ship orders for these Uscom BP+ units in the coming months.

To further our sales pipeline for the Uscom BP+ device, three new UK distributors have been appointed during the Quarter.  These included MediMax Global and Healthwatchers in England and Castleback Health in Ireland.

The Company also presented at a number of global healthcare conferences during the Quarter including the 7TH World Congress on Paediatric and Intensive Care, in Istanbul Turkey. Importantly the USCOM 1A was a featured technology and the subject of a sold out workshop, with standing room only for attendees.

The Company also received notice during the Quarter that a key U.S. patent for the Uscom BP+ device was granted a notice of allowance by the U.S. Patents Office.

Executive Chairman of Uscom, Dr Rob Phillips said “We are very pleased with our progress, particularly our increased revenue and our increased distribution which will support our drive for profitability.  The growing commitment from new distributors in our key markets underpins our belief in the increasing commercial strength of the Company.

We ended the Quarter at close to cashflow breakeven, and with USCOM sales increasing and the first Uscom manufactured Uscom BP+ device shipped, and an expanding distribution, we remain positive for our financial performance in the coming quarters.  We also bolstered our working capital during the Quarter which will be used to support our new distributors and our increased commercial activities.

Uscom now has significant global revenues and great growth opportunities off the back of two practice leading, breakthrough cardiovascular products.”

All figure are in Australian dollars, view the Appendix 4C.

Uscom Manufactures First Australian BP+ Device

June 23rd, 2014

Uscom Limited, an Australian publicly listed medical device Company, is pleased to announce the manufacture of the first Uscom BP+ unit at its head office in Circular Quay, Sydney. The Uscom BP+ is a practice leading, high fidelity, central blood pressure and pulse pressure wave analysis technology based on patent protected suprasystolic oscillometric blood pressure measurements specialised for advanced assessment of hypertension and heart failure.

The first production run of 180 BP+ units, is the final step in the acquisition and integration of Pulsecor assets announced to market in June 2013, and the first step in the global sales and marketing by Uscom of the Uscom BP+. The process has involved the transfer of ownership of all Pulsecor Limited assets, application for and granting of new regulatory approvals, development of new manufacturing specifications and processes, and ultimately assembly of components into the first Uscom BP+ device. The BP+ has both CE Mark and FDA 510K status. Uscom now manufactures 2 premium cardiovascular devices at its Australian centre of operations – the USCOM 1A and now the BP+.

Concurrently management have been appointing new distributors for the BP+ and developing new marketing collateral. Seven new distributors have been appointed covering the UK and China, and they are preparing to sell the BP+ as soon as the relevant regional regulatory approvals permit. Further partnership discussions are continuing, and potential distributors for the remaining global markets are being reviewed.

Executive Chairman of Uscom, Dr Rob Phillips said, “This is a significant milestone for Uscom and a success story for the Australian Medical Device Industry. Uscom now owns and manufactures within Australia two practice leading, noninvasive cardiovascular technologies being exported and sold into global markets. The manufacture of these two devices effectively doubles the size of Uscom, and the strategic power associated with this is difficult to estimate. Our current objectives are to rapidly grow global distribution for both of these products and to exploit the powerful revenue opportunities this creates. We anticipate our new distribution will continue to uptake over the next 18 months and reach optimal revenue impact in mid 2015.”

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the approach to diagnosis and treatment of cardiovascular diseases, including hypertension, heart failure and advanced haemodynamics. The two products are also integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies.

Uscom appoints new US distributor for USCOM 1A monitor

June 16th, 2014

Uscom Limited is pleased to announce the appointment of Unetixs Vascular Inc, Rhode Island USA, as a distributor for the USCOM 1A. Unetixs Vascular Inc is a leading US manufacturer and distributor of vascular monitoring equipment and has been appointed nonexclusive USCOM 1A distributor for the USA for a period of 3 years.

Unetixs is a fully owned subsidiary of Opto Circuits (India) Ltd. Opto is an acquisitive, vertically integrated, global medical technology manufacturer and distributor specialising in primary, acute and critical care products with an annual revenue in the order of $250m USD. Opto acquired the US Companies Criticare in 2008, and Unetixs and Cardiac Science in 2010.

Executive Chairman of Uscom, Rob Phillips said, “Unetixs is an innovative US medical device manufacturer and distributor specialising in cardiovascular assessment devices. The USCOM 1A, as well as being a standard of care in critical care medicine, has an expanding role in monitoring cardiovascular disease and hypertension and is a neat fit with the Unetixs product range. This appointment follows the expansion of Uscom into the field of blood pressure and vascular assessment with the acquisition of the BP+ central blood pressure monitoring device in June last year. Unetixs parent Company, Opto Circuits India Ltd, is a world leader in the field of medical devices for primary, acute and critical care markets with a commitment to rapid global growth and we welcome this partnership.”

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the approach to diagnosis and treatment of cardiovascular diseases, including hypertension and heart failure. The two products are also integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies.

Uscom appoints three new UK distributors for BP+ blood pressure monitor

May 19th, 2014

Uscom Limited is pleased to announce the appointment of three new specialist distributors of the Uscom BP+ suprasystolic oscillometric blood pressure monitor in the UK. MediMax Global and Healthwatchers have been appointed in England, and Castleblack Health in Ireland.

MediMax Global UK Ltd., established in 2007 is an approved accredited supplier to the NHS and NHS Supply Chain in the UK. The business is focused on diagnostic devices and consumables for the detection of cardiovascular and peripheral vascular disease in both primary and secondary care markets and in preventative cardiovascular care. Healthwatchers is a small distributor with expanding programmes in the UK home care and preventative health care markets. Castleblack Health Ltd is a medical device sales company based in Ireland that will promote the Uscom BP+ to the General Practitioner and Cardiology market in Ireland. The BP+ received the CE Mark in February 2014, allowing the Uscom BP+ device to be sold into the European Economic Area.

Executive Chairman of Uscom, Rob Phillips said, “The appointment of these three specialist distributors in the UK will shift our profile and deliver our technology into the hands of new users. Each of these distributors is specialized in the GP and home care clinical markets of hypertension and vascular health, and each have a commitment to disruptive technologies and excellent science. The Uscom BP+ suprasystolic blood pressure monitor suits their sales models perfectly. We are currently preparing to manufacture the Uscom BP+ and these distributors are a vital link in a new network of global BP+ distribution planned to come online in the next 12 months as manufacture increases to meet growing distributor demand.”

The BP+ device uses patent protected “suprasystolic oscillometry” to measure simply and noninvasively central blood pressure at the heart – measurements previously only available with invasive catheters, while older methods measure the pressure in the arm or hand. The unique BP+ measurements provide sensitive information about the health of the heart and vessels that are used to improve management of hypertension. These measurements are an improvement on conventional blood pressure measurements and can be applied in all research and clinical environments. Hypertension affects approximately 25% of all adults worldwide, and the hypertension market is thought to be in excess of $15billion US.

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the way we diagnose and treat cardiovascular diseases, including hypertension and heart failure. The two products are also integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies.

Uscom receives new US Patent notification for BP+ monitor

May 12th, 2014

Uscom Limited is pleased to announce it has received a Notice of Allowance from the US Patents Office for a new US Patent for the non-invasive measurement of suprasystolic blood pressure. The patent method is central to the operations of the Uscom BP+ suprasystolic oscillometric blood pressure monitor.

The BP+ has been recognized as the leading technology for the measurement and monitoring of central blood pressure in an independent study authored by hypertension researchers from Cambridge University, Cambridge, UK, Wales Heart Institute, Cardiff, UK, Weill Cornell Medical College, New York, USA and the University of California, Irvine, USA. The Uscom BP+ has FDA clearance and has completed the CE Mark process to sell into Europe.

Uscom Limited acquired all of the assets of Pulsecor Limited in June 2013, including all IP and manufacturing rights for BP+. The author of the patent and inventor of BP+, Professor Nigel Sharrock is Professor of Anesthesiology at the Weill Cornell Medical College and anesthetist at The New York Hospital for Special Surgery. He is also a member of the Uscom medical advisory board as a specialist in cardiovascular medicine and anesthesia. His interest in the patent has been assigned to Uscom Limited.

Executive Chairman of Uscom, Rob Phillips said, “This patent is central to the operation of the Uscom BP+ suprasystolic blood pressure monitor and joins a suite of patents which protect the BP+ technology commercially in the largest medical device market in the world. It also distinguishes BP+ from other devices using older and less effective technology. We are currently preparing to manufacture the Uscom BP+ and are actively establishing a new network of distribution into the specialized global BP markets.”

The BP+ device uses patent protected “suprasystolic oscillometry” to measure simply and noninvasively central blood pressure at the heart, while older methods measure the pressure in the arm or hand. The unique BP+ measurements provide sensitive information about the health of the heart and vessels and are used to improve management of hypertension. These measurements are an improvement on conventional blood pressure measurements and can be applied in all research and clinical environments. Hypertension affects approximately 25% of all adults worldwide, and the hypertension market is thought to be in excess of $15 billion US.

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the way we diagnose and treat cardiovascular diseases, including hypertension and heart failure. The two products are also integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies.

References:
McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson AB. Central blood pressure: current evidence and clinical importance. Euro Heart J 2014;doi10.1093/eurojeartj/eht565
Avolio A. Central aortic blood pressure and management of hypertension: confirmation of a paradigm shift? Hypertension Editorial 2013; Sept 23

Uscom appoints new Scandinavian distributor

March 10th, 2014

Uscom Limited is pleased to announce the appointment of Avalon Medical AS as an USCOM 1A distributor for the Norway and Sweden markets for 3 years.

Avalon Medical was established in 1997 and operates as a sub-distributor into the Norwegian and Swedish markets for sophisticated medical devices. The Company specialises in high end patient monitoring devices from manufacturers including Welch Allyn, Nihon Kohden and Heinen & Lowenstein, with a focus on the anaesthesia, neonatology and patient monitoring markets. The Company has a number of product specialists with ultrasound and haemodynamics experience in cardiovascular monitoring.

The Norwegian Healthcare budget is the second highest per capita in the world, spending approximately 9.3% of GDP on Healthcare. The Norwegian and Swedish medical device market services approximately 15m people.

Executive Chairman of Uscom, Rob Phillips said, “We are pleased to welcome Avalon Medical to our expanding distribution network. They are a smart company with an established market presence in Norway and Sweden and see value and opportunity in delivering our USCOM 1A into this wealthy market. Norway has a long history with Doppler technologies and we expect a rapid recognition and adoption of our innovative Doppler device.”

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the way we diagnose and treat circulatory disease, including hypertension, heart failure and sepsis. The two products are also integral for optimising cardiovascular management and guidance of fluid, inotropes and vasoactive therapies.

Uscom appoints new German distributor

March 3rd, 2014

Uscom Limited is pleased to announce the appointment of SMT Medical as an USCOM 1A distributor for the German market.

SMT Medical was established 10 years ago and functions as a master distributor into the German market. The Company specialises in innovative cardiovascular products for clinical and research applications and public health programs. The Company has several product specialists with 20 or more years experience in cardiovascular applications and sales of Doppler ultrasound devices. The 3 year contract represents a best endeavours commitment to generate 2.7m AUD revenue over the term of the agreement.

The German medical device market is the third biggest in the world consisting of approximately 500,000 beds and 2,000 Hospitals serving a population of 82m people. The market is also one of the most sophisticated and wealthy supported by a total Healthcare spend of 12% of GDP.

Executive Chairman of Uscom, Rob Phillips said, “We are delighted to appoint SMT to sell USCOM into the wealthy and sophisticated German medical device market. SMT have strong sales channels and an experienced team who understand Doppler ultrasound and recognize the value of the advanced USCOM technology. The appointment of SMT is further evidence of our growing distribution and sales reach, a reach directly connected to revenue.”

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the way we diagnose and treat circulatory disease, including hypertension and heart failure. The two products are also integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies.

Uscom appoints new European distributor

February 27th, 2014

Uscom Limited is pleased to announce the appointment of MedCaT as an USCOM 1A distributor for the Netherlands.

MedCaT is a part of the Feles Medici group delivering sophisticated neurologic and cardiovascular devices into the Netherlands and Germany.

Executive Chairman of Uscom, Rob Phillips said, “The appointment of MedCaT is another step in our expanding distributor network. Distribution and sales lead directly to revenue, and are the key to our business. The appointment of MedCaT is further evidence of our growing distribution and sales focus.”

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the way we diagnose and treat circulatory disease, including hypertension and heart failure, and for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies.

Uscom BP+ new hypertension gold standard in children

February 24th, 2014

Uscom Limited is pleased to note the release of a new validation study comparing the Uscom BP+ measurements of central blood pressure (cBP) with the Sphygmocor (Atcor, Sydney, Australia) in children. The study concluded that the BP+ was at least as accurate as the reference gold standard, but was quick, and easy to use, well tolerated by children and suitable for clinical practice. The independent study was authored by world leading hypertension researchers from New Zealand.

The study compared results of cBP measurements using the Uscom BP+ suprasystolic oscillometry with the Sphygmocor radial artery applanation tonometer in 57 healthy children and found excellent agreement between cBP measures by both devices. The study stated that the tonometric techniques was user dependent, time consuming and challenging, especially when used on young children, and the use of a more simple method, BP+, would be a useful advancement. The BP+ measures the blood pressure close to the heart while the Sphygmocor measures the blood pressure in the wrist and estimates the central blood pressure.

This publication endorsing the BP+ in children follows last weeks publication of a review of cBP evidence in adults by Cambridge University and colleagues which found cBP was better than simple cuff BP measurements, and that the Uscom BP+ was the highest rated cBP device.

The current global BP and hypertension device market is estimated at approximately $2b USD and growing at 11.5% per year. The Uscom BP+ is a break through technology based on patent protected suprasystolic oscillometry and is changing worldwide thinking on hypertension. The Uscom BP+ has FDA clearance and has completed the CE Mark process to sell into Europe and is currently negotiating global distribution, sales and licensing deals to deliver the BP+ to market.

Executive Chairman of Uscom, Rob Phillips said, “This study further endorses the Uscom BP+ as the global leader in cBP technology. The BP+ provides accurate, simple and easy to operate access to cBP measurements and has now been endorsed as the preferred device and adults and children, and is planned for sale at approximately 20% of that of the competing product.”

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the way we diagnose and treat circulatory disease, including hypertension and heart failure, and for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies.

References:
Stoner L, Lambrick DM, Westrupp N, Young J, Faulkner J. Validation of Oscillometric Pulse Wave Analysis Measurements in Children. American Journal of Hypertension 2014, doi:10.1093/ajh/hpt243
Lydakis C, Stefanaki E, Stefanaki S, Thalassinos E, Kavousanaki M, Lydaki D. Correlation of Blood Pressure, Obesity, and Adherence to the Mediterranean Diet with Indices of arterial Stiffness in Children. Eur J Pediatr (2012) 171:1373–1382 DOI 10.1007/s00431-012-1735-3
McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson AB. Central blood pressure: current evidence and clinical importance. Euro Heart J 2014;doi10.1093/eurojeartj/eht565 (The Uscom BP+ is referred to as the Pulsecor Cardioscope II in the study)

Uscom BP+ leading blood pressure technology; Global study

February 10th, 2014

Uscom Limited is pleased to note the release of a new global study of central Blood Pressure (cBP) which identifies cBP as a new clinical standard for hypertension, and Uscom BP+ as the leading device for measuring cBP when compared between 10 market competing devices. The independent study was authored by hypertension researchers from Cambridge University, Cambridge, UK, Wales Heart Institute, Cardiff, UK, Weill Cornell Medical College, New York, USA and the University of California, Irvine, USA.

The study reviewed current evidence supporting adoption of cBP over conventional BP measurement, and ranked cBP devices, awarding the Uscom BP+ a 4 star rating. The study concluded that cBP better predicts cardiovascular risk than conventional arm cuff blood pressure measurements, and that treatment based on cBP is likely to improve diagnosis and management of hypertension. In their assessment of the clinical applicability of current on-market devices, the BP+ technology was awarded 4 stars along with the Centron device. Other devices manufactured by Omron, Atcor, Skidmore, Tensiomed and HealthSTATS, all received 1 to 3 stars.

The current global BP device market is estimated at approximately $2b USD and growing at 11.5% per year. The Uscom BP+ is a break through BP technology based on patent protected suprasystolic oscillometry which is changing worldwide thinking on BP and hypertension treatment. The Uscom BP+ has FDA clearance and has completed the CE Mark process to sell into Europe.

Executive Chairman of Uscom, Rob Phillips said, “This review of the current science by the world’s leading hypertension experts comes at a great time for us as we negotiate global distribution and licensing agreements for BP+. The study confirms that cBP is the new gold standard measurement for hypertension, and that the Uscom BP+ is the gold standard cBP technology. As the rest of the world begins the upgrade from conventional BP to cBP technology, Uscom BP+ is a technology of choice, and we are now preparing to manufacture the device to meet this demand.”

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the way we diagnose and treat circulatory disease, including hypertension and heart failure, and for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies.

References:
McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson AB. Central blood pressure: current evidence and clinical importance. Euro Heart J 2014;doi10.1093/eurojeartj/eht565
Avolio A. Central aortic blood pressure and management of hypertension: confirmation of a paradigm shift? Hypertension Editorial 2013; Sept 23

Uscom BP+ receives CE Mark for sales into Europe

February 4th, 2014

Uscom Limited today announced receipt of the CE Mark for the BP+, allowing the Uscom BP+ device to be sold into the European Economic Area. The Uscom BP+ already has FDA 510K status and is currently in the process of TGA review.

In anticipation of the confirmation of CE status Uscom has been developing a European distribution network and volume manufacturing strategy so that the BP+ can be rapidly delivered to market to meet demand.

The Uscom BP+ is a practice leading blood pressure (BP) measurement device based on patent protected suprasystolic oscillometric technology. While conventional methods measure BP in the arm, the BP+ directly measures blood pressure at the heart, a more effective approach. The BP+ also provides unique central pulse pressure waveforms that have previously only been acquired using catheters into the heart. These accurate noninvasive central BP measurements are revolutionising the way hypertension and heart failure are diagnosed and managed with central BP now being proven to be more predictive of outcomes and a better method to guide hypertension treatment.

Executive Chairman of Uscom, Rob Phillips said, “The Uscom BP+ technology is leading the changes in thinking on blood pressure and hypertension globally. The confirmation of the completion of the CE Mark process means we can now sell the device into European jurisdictions. We are also preparing for increased manufacturing of the BP+ to meet current orders and to feed the product into our newly developed European distribution channels. The Uscom BP+ is an excellent complement to the USCOM 1A cardiac output monitor in our portfolio as both are breakthrough products.”

The USCOM 1A and Uscom BP+ technologies are premium cardiovascular devices manufactured and distributed by Uscom Limited and sold into global markets. The BP+ simplifies and improves the accuracy of blood pressure measurement and management and is used as a research tool and clinical device for advanced management of hypertension.

References:
McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson AB. Central blood pressure: current evidence and clinical importance. Euro Heart J 2014
Avolio A. Central aortic blood pressure and management of hypertension: confirmation of a paradigm shift? Hypertension Editorial 2013; Sept 23

Uscom appoints Deltex to distribution team

January 29th, 2014

Uscom Limited today announced execution of a three year distribution and market collaboration agreement with Deltex Medical Group PLC (AIM code: DMEG), UK. The agreement appoints Deltex as a nonexclusive distributor for the USCOM 1A, and establishes the foundations for further collaboration in the delivery of Doppler technologies to the global cardiovascular monitoring market.

Deltex manufactures and markets the CardioQ-ODM Oesophageal Doppler Monitor (ODM) and has excellent representation in the UK NHS system, as a leading proponent and adopter of Doppler haemodynamic monitoring. The ODM is marketed for peri-operative and intra-operative surgical monitoring with the Deltex business model based on sales of single patient disposable probes. The USCOM 1A is noninvasive with widespread application in sepsis, heart failure and hypertension in neonates, children, adults and the elderly and is marketed as a single capital sale. The devices are complementary and have practice leading clinical evidence, and both companies are committed to growing the cardiac output monitoring market aggressively, by expansion into routine clinical practice in addition to replacement of invasive and less accurate technologies with safe and accurate Doppler ultrasound technologies.

Deltex has 24 direct sales staff and educators in the sophisticated UK market, and a further 10 in the US. Deltex also has channels into Europe, Eastern Europe, the Middle East and Africa. It is planned that USCOM will be introduced into the additional Deltex distribution channels, and the ODM will be introduced into current Uscom distribution channels over the next twelve months. This partnership represents a collaboration between the two major Doppler cardiac monitoring companies to better exploit growing market opportunities, and is in response to the increasing recognition by clinicians of the clinical importance of Doppler cardiac monitoring. The best endeavours agreement is targeted to generate A$582k revenue to Uscom in year one.

Executive Chairman of Uscom, Rob Phillips said, “This Doppler partnership shifts the cardiac monitoring landscape. Doppler is now a clear lead technology in the sophisticated cardiovascular monitoring market, and Uscom and Deltex lead this field. Deltex have excellent sales, education and clinical support channels, particularly into the UK market and this partnership delivers USCOM into these new global sales and distribution channels. This partnership will generate immediate revenue for both companies, provide for market growth and market consolidation, and establish a foundation for longer term strategic opportunities.”

Deltex’s CEO, Ewan Phillips said, “Uscom and Deltex have identified opportunities to sell their complimentary technologies into their existing customer bases. The partnership expands the breadth of each company’s clinical offer and allows both companies to further differentiate the strengths of Doppler ultrasound haemodynamic monitoring and measurement.”

The USCOM 1A and ODM technologies are complementary and used to simplify and improve cardiovascular diagnosis, management and monitoring in different clinical environments.

References:
www.deltexmedical.com
National Health Scheme Technology Adoption Centre. Intraoperative Fluid Management Technologies Adoption Pack